← Leaderboards
G Scott Long
University Of Pittsburgh At Pittsburgh
$3,034
Attributed
$3,034
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$3,034 · 1
By mechanism
M01$3,034 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Donald L Trump$24,661,732
- Mitchell D Creinin$2,236,079
- Candace S Johnson$18,922,226
- Ramesh Ramanathan$303,574
- Jennifer R Grandis$109,711,044
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchClinical Trial Phase ICombination ChemotherapyDoxorubicinDrug InteractionsHuman SubjectHuman Therapy EvaluationInjection /InfusionNeoplasm /Cancer ChemotherapyOctreotidePharmacokineticsSomatostatin
Grant awards (4)
PHASE I STUDY OCTREOTIDE ACETATE (SANDOSTATIN) AS BIOMODULAR DOXORUBIN$0
M01 · FY2002 · RR
PHASE I STUDY OCTREOTIDE ACETATE (SANDOSTATIN) AS BIOMODULAR DOXORUBIN$0
M01 · FY2002 · RR
PHASE I STUDY OCTREOTIDE ACETATE (SANDOSTATIN) AS BIOMODULAR DOXORUBIN$0
M01 · FY2001 · RR
PHASE I STUDY OCTREOTIDE ACETATE (SANDOSTATIN) AS BIOMODULAR DOXORUBIN$3,034
M01 · FY2000 · RR